NEW YORK (GenomeWeb) – Monsanto announced two new licensing agreements for genome editing technologies with Israel's TargetGene Biotechnologies and Germany's Nomad Bioscience.

Under the terms of the TargetGene agreement, Monsanto has obtained an exclusive license to the firm's genome editing engine (T-Gee) and an equity position in the privately owned firm. T-Gee is based on RNA-directed gene targeting, the firms said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.